why choose us

First received: January 13, 2023

Clinical Trial: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumor

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Multicenter, Phase 1 Study of IGM-7354 in Adult Participants With Relapsed and/or Refractory Cancer

Brief Summary: This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to evaluate the safety, tolerability, and PK of IGM-7354 in participants with relapsed and/or refractory tumors.The study design consists of a dose-escalation stage and dose-expansion stage.Study participation will consist of a 28-day screening period, a treatment period, and a safety follow-up period 90-days after the last dose.

Read more